{"entity":{"id":"pathos-ai","kind":"company","name":"Pathos AI","aka":[],"tldr":"Pathos AI trains multimodal artificial intelligence models on millions of cancer patients' genomic, imaging, text and outcome records to choose which experimental drugs to develop and which patients to test them in. It has licensed a TROP2/HER3 bispecific antibody-drug conjugate and an oestrogen receptor degrader, and raised a 365 million dollar Series D in 2025.","summary":"Pathos AI is an AI-enabled, clinical-stage oncology biotech. Its PATHOS platform draws on millions of oncology records integrating genomics, transcriptomics, imaging, text and longitudinal outcomes, and is building what the company describes as the largest multimodal foundation model in oncology to select assets, design trials and discover biomarkers. In August 2026 it licensed JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate, from Alphamab Oncology ($125 million upfront, up to $2,093 million in milestones) and agreed a co-exclusive licence to take the oestrogen receptor PROTAC degrader AZD4241 into the clinic for ER-positive breast cancer. In May 2026 it took a majority stake in DeuterOncology (MET inhibitor). Pathos raised a $365 million Series D in May 2025 at a post-money valuation of about $1.6 billion.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.pathos.com/"},{"label":"Series D press release (May 2025)","url":"https://www.pathos.com/pathos-ai-secures-365-million-in-series-d-financing-to-advance-oncology-drug-development-through-ai"},{"label":"News page","url":"https://www.pathos.com/news"}],"tags":[],"related":[],"cancers":["breast-hr-positive","nsclc"],"sections":["ai-computation","drug-discovery","adcs"],"technologies":["pathology-foundation-model","ai-drug-design","bispecific-adc","protac-degrader","kinase-inhibitors"],"targets":["trop2","her3","estrogen-receptor","met"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06785636"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The Series D release dateline is New York, NY rather than Chicago; Chicago may be an operating base but is not stated on fetched pages. Series D investors were not named. The AstraZeneca counterparty for AZD4241 is inferred from the asset code on the company news page, not stated in the fetched text. Tempus partnership not mentioned on fetched pages. companyType set to biotech because the company develops drugs; it also fits ai-software."],"hq":"New York, NY","country":"US","companyType":"biotech","website":"https://www.pathos.com/","stage":"growth","investors":[],"funding":[{"round":"Series D","year":2025,"amountUsd":365000000,"source":"https://www.pathos.com/pathos-ai-secures-365-million-in-series-d-financing-to-advance-oncology-drug-development-through-ai","note":"Post-money valuation about $1.6 billion, May 2025; investors not named in the release."}]},"route":"/companies/pathos-ai/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"technology":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/"},{"id":"pathology-foundation-model","kind":"technology","name":"Pathology & radiology foundation models","route":"/technologies/pathology-foundation-model/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"},{"id":"her3","kind":"target","name":"HER3","route":"/targets/her3/"},{"id":"met","kind":"target","name":"MET","route":"/targets/met/"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"trial":[{"id":"nct06785636","kind":"trial","name":"A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC","route":"/trials/nct06785636/"}],"roadmap":[{"id":"ai-oncology-roadmap","kind":"roadmap","name":"AI in oncology roadmap: pattern readers → foundation models → agents in the workflow","route":"/roadmaps/ai-oncology-roadmap/"}]}}